Applicant's Details |
* Name: |
|
Home telephone: |
Work telephone: |
Mobile telephone: |
|
(Please enter at least one of the Telephone numbers.) |
* E-mail: |
|
* Education (highest degree achieved) |
|
* Current Employer |
|
* Functional area where employed |
|
* Area of Interest: |
|
* Position for which you are applying: |
|
* How did you first hear of us:
|
If Other, please specify: |
|
|
* Current/most recent base salary: | $
(Please enter the exact yearly dollar figure in US dollars.) |
* Current/most recent bonus expectation: | $
(Please enter the exact yearly dollar figure in US dollars.) |
* Minimum acceptable compensation (salary plus bonus): | $
(Please enter the exact yearly dollar figure in US dollars. Please provide a thoughtful response to this question. Compensation expectations that significantly exceed norms for the position in question may exclude a candidate from further consideration for that position.) |
* Are you working now? |
|
* Are you self employed? |
|
* Are you willing to relocate to any of the following locations? (Check all that apply) |
|
* Chapel Hill, NC (headquarters): |
|
* NJ/ NY/ Philadelphia field office (work from home) |
|
* Chicago / Midwest Field Office (work from home) |
|
* California Field Office (work from home) |
|
* Do you require sponsorship to work in the U.S.? |
|
* What is your earliest possible start date? |
(mm/dd/yyyy) |
* How much notice are you required to give your current employer (if working)? |
(number of weeks) |
* Subject to non-solicitation of current co-workers? |
|
* Subject to non-solicitation of current clients or business contacts? |
|
* Restricted in any way as to ongoing client involvement/engagements? |
|
* Restricted in any way as to competitors of current employer? |
|
* Have you ever been debarred from the pharmaceutical industry by the U.S. Food and Drug Administration pursuant to 21 U.S.C. 335(a)? |
|
Please list 2-3 references |
|
* Cover Letter: |
|
* Resume: |
|
Addtional Document 1: |
|
Addtional Document 2: |
|
Addtional Document 3: |
|